Ensifentrine improves outcomes in COPD, but unlikely to be cost effective
When added to maintenance therapy for moderate to severe COPD, ensifentrine improves lung function and exacerbation rate vs. placebo, according to a draft evidence report by the Institute for Clinical and Economic Review.However, models in the Institute for Clinical and Economic Review (ICER) draft evidence report suggested ensifentrine (Verona Pharma), a novel inhaled dual PDE-3 and PDE-4